Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Results from two parallel trials suggest that withholding methotrexate only after the second dose of a COVID vaccine is safe and effective in patients with rheumatoid arthritis or psoriatic arthritis.
New research in a mouse model of osteoarthritis shows that the RNA-binding protein Lin28a is expressed in chondrocytes and limits cartilage damage by inhibition of Let-7 microRNAs.
New research suggests that the pro-inflammatory effects of TNF on rheumatoid arthritis synovial fibroblasts are mediated by extracellular sulfatase Sulf2, which could present a novel target for treatment.
A short questionnaire designed for use by dermatologists to screen patients with psoriasis can be used for the selection of individuals for MRI assessment of axial psoriatic arthritis.
New research sheds light on how disruption of peripheral circadian rhythms mediates inflammation-induced intervertebral disc degeneration and suggests a therapeutic approach to target these mechanisms.
The newly developed Z583 is a potent and highly specific inhibitor of JAK3, with a favourable in vitro and in vivo safety profile and effectiveness in treatment of collagen-induced arthritis in mice.
A new study reveals a non-canonical function for the histone demethylase JMJD1C that restrains plasma cell differentiation and protects mice from experimental arthritis.
New findings support the existence of an antigen presentation-independent mechanism known as the ‘cusp theory’ and the involvement of a newly discovered ‘lupus epitope’ in systemic lupus erythematosus susceptibility.
New research attempts to explore the cause of plasmacytoid dendritic cell hyperactivation in systemic lupus erythematosus by focusing on genetic risk variation.
The findings of a new study suggest that the adipokine FABP4 promotes multiple pathological changes in rheumatoid arthritis and could represent a new therapeutic target.
Three new reports of results from two clinical trials of bimekizumab indicate that it is safe and efficacious for the long-term treatment of patients with ankylosing spondylitis or psoriatic arthritis.
A new study uncovers a protective role for epidermal S100A9 in psoriasis and psoriatic arthritis, and highlights this alarmin as a potential biomarker of disease progression.